ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe
September 05, 2024 02:35 ET
|
Advanz Pharma
ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The European Commission’s decision to revoke the OCALIVA®...
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)
September 03, 2024 04:00 ET
|
Advanz Pharma
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
August 29, 2024 14:14 ET
|
Spherix Global Insights
EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...
Grapefruit/IGNG and Pacific Banking Corp Announce Signing a Reseller Letter of Intent to Expand Cannabis Banking Services into Southern California.
January 15, 2020 06:00 ET
|
Imaging3, Inc.
Los Angeles & Desert Hot Springs, California, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Grapefruit Boulevard Investments, Inc., (“GBI”) a licensed and fully compliant California based cannabis...
Premier Boxing Champions Series Opens 2017 With a Smash
February 02, 2017 10:00 ET
|
Premier Boxing Champions, Al Haymon Boxing
Next Five Weeks Includes Two Blockbuster Primetime Network Shows The Return of Heavyweight Champion Deontay Wilder; and Welterweight Mega-Fight Between Champions Danny Garcia and Keith Thurman LAS...
CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
May 31, 2016 07:00 ET
|
CymaBay Therapeutics, Inc.
Study stopped early after review of safety and efficacy data demonstrated clear proof-of-concept and opportunity for further dose reduction to optimize clinical safety and efficacyLarge...